CRISPR-Cas9 technology offers promising possibilities for DM1 treatment by removing the pathogenic CTG expansion from the DMPK mutant allele or using a nuclease-free derivative to slow DMPK transcription by targeting the CTG repeats. The gene discussed is DMPK; the disease is myotonic dystrophy type 1.